Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the sale of Calavo Growers, Inc. to Mission Produce, Inc. for $14.85 in cash and 0.9790 shares of Mission for each share of Calavo [1] Group 1: Investigation Details - The investigation focuses on whether Calavo and its board violated federal securities laws and/or breached fiduciary duties by not obtaining the best possible consideration for shareholders [2] - Concerns include whether Mission is underpaying for Calavo and if all material information necessary for shareholders to assess the merger consideration was disclosed [2] Group 2: Potential Actions - On behalf of Calavo shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures, and other relief related to the proposed transaction [3] - The firm operates on a contingent fee basis, meaning shareholders would not incur out-of-pocket legal fees or expenses [3] Group 3: Firm Background - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having recovered millions for defrauded investors [4]

Core Viewpoint - CorMedix Inc. is under investigation for potential violations of federal securities laws following a significant revenue guidance reduction due to changes in reimbursement policy for its product DefenCath [1][2]. Financial Performance - CorMedix announced preliminary fourth quarter and full year 2025 results, revealing a revenue guidance cut from $400 million to a range of $300 million to $320 million [2]. - The anticipated reimbursement policy change for DefenCath is expected to significantly reduce institutional reimbursement levels and net pricing in the second half of 2026 [2]. Market Reaction - Following the announcement of the revenue guidance reduction, CorMedix's stock price fell over 21%, opening at $8.73 per share [2].

Core Viewpoint - Aquestive Therapeutics, Inc. is under investigation for potential violations of federal securities laws following an FDA letter identifying deficiencies in its NDA application for Anaphylm, leading to a significant drop in stock price [1][2]. Group 1: Company Overview - Aquestive Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for serious medical conditions, including anaphylaxis [1]. - The company’s stock price fell by $2.18 (35.1%) to open at $4.03 in response to the FDA's findings [2]. Group 2: Regulatory Impact - The FDA's letter indicates that the deficiencies in the NDA application preclude any discussions regarding labeling and post-market commitments for Anaphylm [1]. - This regulatory setback could have significant implications for the company's market position and future revenue potential [1]. Group 3: Legal Implications - Levi & Korsinsky has initiated an investigation into the company, indicating potential legal ramifications for shareholders who may have suffered losses [2]. - The firm has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [3].

Core Viewpoint - Ultragenyx Pharmaceutical Inc. is under investigation for potential violations of federal securities laws following the failure of its Phase III studies for setrusumab (UX143) in treating Osteogenesis Imperfecta, leading to a significant drop in stock price [1][2][3] Group 1: Study Results - The Phase III Orbit and Cosmic studies did not meet their primary endpoint of reducing annualized clinical fracture rates compared to placebo and biophosphonates, respectively [2] - Although secondary endpoints showed improvements in bone material density, these did not correlate with a statistically significant reduction in fractures in either study [2] Group 2: Financial Impact - Following the announcement of the study results, Ultragenyx's stock price fell by $14.87, a decrease of 43.49%, opening at $19.32 per share on December 29, 2025 [3] - The stock decline has resulted in a new 52-week low, significantly below the previous low of $25.81 [3] Group 3: Company Response - Ultragenyx has indicated it will implement significant expense reductions in response to the study outcomes [2]

Core Viewpoint - AST SpaceMobile, Inc. is under investigation for potential violations of federal securities laws following the delay of its BlueBird 6 satellite launch, which has impacted its stock price significantly [1][2]. Group 1: Company Developments - AST SpaceMobile's BlueBird 6 satellite launch was initially scheduled for December 15, 2025, but has been delayed to December 21, 2025, due to prolonged pre-launch integration and testing by the Indian Space Research Organisation (ISRO) [2]. - The company has not yet issued a detailed public statement regarding the reasons for the launch delay [2]. Group 2: Market Reaction - Following the announcement of the launch delay, AST SpaceMobile's stock price fell by $6.51, representing a 9.52% decrease, closing at $61.86 per share on December 17, 2025 [2]. Group 3: Legal Context - Levi & Korsinsky has initiated an investigation into AST SpaceMobile for potential securities law violations, inviting investors who suffered losses to explore recovery options [1][3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Cogent Communications Holdings, Inc. and its officers or directors [1] Financial Performance - On November 6, 2025, Cogent reported a year-over-year service revenue decline of nearly 6% for the third quarter of 2025 [3] - The company announced a drastic dividend cut of 98%, reducing it from $1.015 per share to $0.02 per share [3] - Following the announcement, Cogent's stock price dropped by $13.35 per share, or 34.86%, closing at $24.95 per share on the same day [3]

Core Viewpoint - Apogee Enterprises, Inc. is under investigation by Block & Leviton for potential securities law violations following a significant drop in share price and disappointing quarterly results [1][2]. Financial Performance - Apogee Enterprises' shares fell over 13% during intraday trading on January 7, 2026, after the company reported quarterly results that did not meet analyst expectations [2]. - The company lowered its full-year outlook due to weaker demand and margin pressure specifically in its Architectural Glass segment [2]. Management Changes - On the same day as the earnings report, Apogee announced the resignation of its Chief Financial Officer, Matthew Osberg, effective January 16, 2026 [2]. Legal Investigation - Block & Leviton is investigating whether Apogee committed securities law violations and may pursue legal action to recover losses for affected investors [4]. - Investors who have lost money on their Apogee investments are encouraged to contact Block & Leviton for potential recovery options [5]. Whistleblower Information - Individuals with non-public information about Apogee are encouraged to assist in the investigation or report to the Securities Exchange Commission under the whistleblower program, which offers rewards of up to 30% of any successful recovery [6]. Firm Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the merger between Allegiant Travel Company and Sun Country Airlines for Allegiant shareholders, as they will own approximately 67% of the combined entity upon completion of the transaction [1]. Group 1: Investigation Details - The investigation focuses on whether Allegiant and its board violated federal securities laws or breached fiduciary duties by not securing the best possible consideration for shareholders and failing to disclose all material information necessary for assessing the merger [3]. - Halper Sadeh LLC may seek increased consideration for Allegiant shareholders, additional disclosures, and other forms of relief related to the proposed transaction [4]. Group 2: Legal Rights and Options - Allegiant shareholders are encouraged to learn more about their legal rights and options regarding the merger through Halper Sadeh LLC [2].

Core Viewpoint - BellRing Brands, Inc. is under investigation for potential violations of federal securities laws, with concerns regarding the sustainability of its sales growth driven by temporary inventory loading rather than genuine consumer demand [1][2]. Company Overview - BellRing Brands operates in the convenient nutrition category, primarily known for its brands Premier Protein and Dymatize, which offer ready-to-drink protein shakes and powders [2]. Sales Performance - The company reported that Premier Protein achieved an all-time high in household penetration and strong demand across all channels, attributed to distribution expansion and promotional activities [2]. - However, the actual sales growth may have been artificially inflated due to temporary trade inventory loading at key retailers [2]. Stock Price Reaction - On May 5, 2025, BellRing disclosed that several key retailers reduced their inventory levels, which would negatively impact growth in Q3 2025. Following this announcement, the stock price dropped by $13.96, or over 18%, from $77.34 to $63.38 per share [3]. - On August 4, 2025, the company announced disappointing quarterly consumption figures for Premier Protein RTD Shakes, leading to a further decline in stock price by $17.46, or nearly 33%, from $53.64 to $36.18 per share [4].

Core Viewpoint - The law firm Halper Sadeh LLC is investigating the fairness of the sale of ON24, Inc. to Cvent for $8.10 per share in cash, focusing on the rights of ON24 shareholders [1][2]. Group 1: Investigation Details - The investigation aims to determine if ON24 and its board violated federal securities laws or breached fiduciary duties by not securing the best possible deal for shareholders [2]. - Specific concerns include whether Cvent is underpaying for ON24 and if all material information necessary for shareholders to assess the merger was disclosed [2]. Group 2: Potential Actions - Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures, and other forms of relief related to the proposed transaction [3]. - The firm operates on a contingent fee basis, meaning shareholders would not incur out-of-pocket legal fees or expenses [3].